HomeCompareASXC vs GBDC

ASXC vs GBDC: Dividend Comparison 2026

ASXC yields 574.88% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ASXC wins by $183635.13M in total portfolio value
10 years
ASXC
ASXC
● Live price
574.88%
Share price
$0.35
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$183655.98M
Annual income
$136,833,479,194.82
Full ASXC calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — ASXC vs GBDC

📍 ASXC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodASXCGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ASXC + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ASXC pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASXC
Annual income on $10K today (after 15% tax)
$48,864.62/yr
After 10yr DRIP, annual income (after tax)
$116,308,457,315.60/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, ASXC beats the other by $116,294,474,191.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASXC + GBDC for your $10,000?

ASXC: 50%GBDC: 50%
100% GBDC50/50100% ASXC
Portfolio after 10yr
$91838.41M
Annual income
$68,424,964,964.33/yr
Blended yield
74.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

ASXC
Analyst Ratings
2
Hold
Consensus: Hold
Price Target
$1.50
+331.2% upside vs current
Range: $1.50 — $1.50
Altman Z
-41.9
Piotroski
3/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASXC buys
0
GBDC buys
0
No recent congressional trades found for ASXC or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricASXCGBDC
Forward yield574.88%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$183655.98M$20.85M
Annual income after 10y$136,833,479,194.82$16,450,733.83
Total dividends collected$179712.33M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy
Analyst price target$1.50$14.00

Year-by-year: ASXC vs GBDC ($10,000, DRIP)

YearASXC PortfolioASXC Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$68,188$57,487.78$12,492$1,791.70+$55.7KASXC
2$439,313$366,351.83$16,527$3,160.58+$422.8KASXC
3$2,675,944$2,205,879.72$23,588$5,904.90+$2.65MASXC
4$15,420,706$12,557,445.87$37,141$11,901.65+$15.38MASXC
5$84,130,987$67,630,830.90$66,205$26,463.38+$84.06MASXC
6$434,856,205$344,836,049.27$137,452$66,612.65+$434.72MASXC
7$2,131,079,702$1,665,783,562.49$342,372$195,298.53+$2130.74MASXC
8$9,909,627,711$7,629,372,430.43$1,053,292$686,954.33+$9908.57MASXC
9$43,759,343,910$33,156,042,258.68$4,111,439$2,984,416.95+$43755.23MASXC
10$183,655,977,178$136,833,479,194.82$20,849,974$16,450,733.83+$183635.13MASXC

ASXC vs GBDC: Complete Analysis 2026

ASXCStock

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.

Full ASXC Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this ASXC vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASXC vs SCHDASXC vs JEPIASXC vs OASXC vs KOASXC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.